Sedating Drug “Operating Machinery” Warnings Need Clarification – FDAer
This article was originally published in The Tan Sheet
Executive Summary
Label statements advising "use caution when operating machinery" do not adequately communicate the risks consumers face from potentially sedating or impairing drugs, an FDA rep said Nov. 15
You may also be interested in...
Allegra Marketing Strategy “Drives On” In Response To Claritin Switch
Aventis will not change its marketing strategy for Allegra following the Rx-to-OTC switch of Schering-Plough's Claritin
Antihistamine switch
CDER expects to reach decision by year-end on whether to switch Rx low- and non-sedating antihistamines Claritin (Schering-Plough), Allegra (Aventis) and Zyrtec (Pfizer) without sponsor consent. In May, FDA's Nonprescription and Pulmonary-Allergy Drugs Advisory Committees found the drugs safe for use in an OTC setting. Issues related to sedation warnings on currently available OTC antihistamines were discussed at a joint FDA/NTSB meeting Nov. 14-15 (1"The Tan Sheet" Nov. 19, p. 3)...
Drug-Impaired DUI Detection Government Support Advocated By Deputy AG
Government agencies should provide law enforcement with more resources to detect and prosecute drivers impaired by legally-marketed drugs, Delaware Deputy Attorney General William George stated at an FDA/ National Transportation Safety Board joint meeting